Testing and interpreting measures of ovarian reserve: a committee opinion
Alan S. PenziasRicardo AzzizK. BendiksonTommaso FalconeKarl R. HansenMicah J. HillWilliam W. HurdSangita JindalSuleena Kansal KalraJennifer MersereauCatherine RacowskyRobert W. RebarRichard H. ReindollarChevis N. ShannonAnne Z. SteinerDale W. StovallCigdem TanrikutHugh S. TaylorBelinda J. Yauger
414
Citation
104
Reference
10
Related Paper
Citation Trend
Keywords:
Ovarian Reserve
Anti-Müllerian hormone
Anti-Müllerian hormone
Ovarian Reserve
Müllerian mimicry
Cite
Citations (0)
Anti-Müllerian hormone
Ovarian Reserve
Cite
Citations (12)
BACKGROUNDTo assess the impact of ovarian cystectomy for endometriomas on the ovarian reserve, we evaluated the pre- and post-operative levels of serum anti-Müllerian hormone (AMH). We also analyzed the correlations between factors related to endometriosis and surgery for endometriomas and the serum AMH levels to investigate which factors affect ovarian reserve.
Anti-Müllerian hormone
Ovarian Reserve
Cite
Citations (193)
Anti-Müllerian hormone
Ovarian Reserve
Antral follicle
Cite
Citations (16)
Ovarian Reserve
Anti-Müllerian hormone
Antral follicle
Cite
Citations (0)
Anti-Müllerian hormone (AMH) is a member of the transforming growth factor (TGF)-beta superfamily and mainly expressed by the granulosa cells of ovarian follicles. In women AMH is only expressed in ovarian follicles and therefore can be used for the evaluation of the ovarian reserve function and the prediction of ovary ageing and ovarian response during in vitro fertilization (IVF) treatment. This article summarizes the clinical application of AMH, especially in evaluating ovarian reserve functions.
Anti-Müllerian hormone
Ovarian Reserve
Cite
Citations (1)
Anti-müllerian hormone (AMH) is produced by granulosa cells of small, growing follicles in the ovary. Serum AMH levels strongly correlate with the number of growing follicles, and therefore AMH has received increasing attention as a marker for ovarian reserve. This review summarizes recent findings and limitations in the application of serum AMH in ovarian reserve assessment.A PubMed search was conducted to find recent literature on the measurements and use of serum AMH as a marker for ovarian reserve.Serum AMH levels are measured to assess the "functional ovarian reserve," a term that is preferred over "ovarian reserve," since AMH levels reflect the pool of growing follicles that potentially can ovulate. Serum AMH levels are used in individualized follicle-stimulating hormone dosing protocols and may predict the risk of poor response or ovarian hyperstimulation syndrome but has limited value in predicting ongoing pregnancy. Serum AMH levels are studied to predict natural or disease-related age of menopause. Studies show that the age-dependent decline rates of AMH vary among women. The generalized implementation of serum AMH measurement has also led to an increase in diagnostic assays, including automated assays. However, direct comparison of results remains problematic.Serum AMH remains the preferred ovarian reserve marker. However, the lack of an international standard for AMH limits comparison between AMH assays. Furthermore, little is known about endogenous and exogenous factors that influence serum AMH levels, which limits proper interpretation of AMH values in a clinical setting.
Anti-Müllerian hormone
Ovarian Reserve
Cite
Citations (334)
Anti-müllerian hormone (AMH) has been suggested as a marker for the quantity of oocytes remaining within the ovaries (ovarian reserve). It was shown to correlate with antral follicle counts (AFC), outcomes from ovarian stimulation, and onset of menopause. Thus, AMH was previously considered to be the ideal marker of ovarian reserve because it is exclusively produced by granulosa cells and is the only marker that was thought to be stable throughout the menstrual cycle. However, recent studies demonstrate fluctuations in AMH levels during the menstrual cycles, questioning the utility of AMH as a marker of oocyte quantity.We report the case of a 32-yr-old Gravida 0 woman with idiopathic hypogonadotropic hypogonadism who presented for fertility treatment with unstable AMH levels.The patient's initial FSH and LH levels were both below 1.0 mIU/ml. Estradiol was 28 pg/ml. Her initial AMH and AFC were 0.20 ng/ml and 0, respectively. She underwent three cycles of fertility treatment.During the 16-wk course of treatment with human menopausal gonadotropins, normal follicular development was observed. Both AMH and AFC gradually increased during treatment and peaked at 1.26 ng/ml and 6, respectively. On the third cycle of treatment, she successfully conceived.In the case of idiopathic hypogonadotropic hypogonadism, AMH concentration increases because human menopausal gonadotropin stimulates the growth of FSH-dependent follicles. Thus, AMH has limitations because it only reflects the growing follicular pool that is responsive to gonadotropins. Therefore, AMH may not be solely reflective of the underlying primordial pool.
Anti-Müllerian hormone
Ovarian Reserve
Müllerian mimicry
Cite
Citations (65)
Ovarian Reserve
Anti-Müllerian hormone
Cite
Citations (0)
Anti-Müllerian hormone
Ovarian Reserve
Cite
Citations (3)